parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.07 from other evidence	0.00
cell type Human Protein Atlas	group enriched, including oligodendrocytes; strongest in schwann cells	0.75
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	7 Parkinson's papers of 3,192	0.73
pathways Reactome	4 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 3968

receipt 3978: SOX10 in dopamine neurons, braak

power: full sample +0.31 (p 0.204, n 18), 95% CI -0.18 to +0.68. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.37 (p 0.135, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.43 (p 0.074, n 18). could be the mix.
skeptic: leave-one-out range +0.22 to +0.43, sign flips 0; without severely affected donors +0.31 (p 0.204, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SOX10 in dopamine neurons.

case closed: nothing better to follow up.

receipt 3977: SOX10 in oligodendrocytes, braak

power: full sample -0.10 (p 0.683, n 18), 95% CI -0.54 to +0.38. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.07 (p 0.781, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.03 (p 0.922, n 18). could be the mix.
skeptic: leave-one-out range -0.26 to -0.00, sign flips 0; without severely affected donors -0.10 (p 0.683, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SOX10 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts